TAO Synergies (TAOX) Non Operating Investment Income (2025 - 2026)
TAO Synergies' (TAOX) quarterly Non Operating Investment Income came in at -$8.4 million in Q2 2026, down 58621.57% on a YoY basis from N/an in Q2 2025, and down 2505.52% quarter-over-quarter from $350740.0 in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) Non Operating Investment Income (2025 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Non Operating Investment Income for 2 consecutive years, with -$8.4 million the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | 36.64 Mn |
| 10 | TAO Synergies | 30.93 Mn | 30.93 Mn | - | -8.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.44 Mn |
| Mar 31, 2026 | 350,740.00 |
| Jun 30, 2025 | -14,368.00 |